Natco Pharma Q2 Results FY27: PAT Falls 60.88%, Revenue Rs 967.30 Cr, PAT Rs 202.60 Cr

November 13, 2026
Posted by: Harsh Piplani
Category: Results

Quick Answer

Natco Pharma Q2 Results FY27 were declared on 13 November 2026, with revenue that fell 29.03% YoY to Rs 967.30 Cr from Rs 1,363.00 Cr, while net profit fell 60.88% YoY to Rs 202.60 Cr from Rs 517.90 Cr. These quarterly results on a consolidated basis show revenue with no YoY growth, as it fell 29.03%, and the YoY growth picture is the first thing to read in the Financial Highlights table below.

Natco Pharma Ltd (NATCOPHARM) Q2 Results FY27 announced on 13 November 2026, covering the company’s financial performance for the July to September 2026 quarter. The Consolidated results show revenue of Rs 967.30 Cr and PAT of Rs 202.60 Cr in Natco Pharma Q2 Results FY27, and the results date of 13 November 2026 sets the reference point for every comparison in this article.

This Univest results analysis of Natco Pharma Q2 Results covers the financial highlights, business drivers, outlook and risks, and it opens with the Financial Highlights table that sits below.

Click Here – Get Free Investment Predictions

Table of Contents

Natco Pharma Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 967.3 Cr	Rs 1363 Cr	-29.03% YoY
Operating Profit	Rs 257.9 Cr	Rs 579.2 Cr	-55.47% YoY
Net Profit (PAT)	Rs 202.6 Cr	Rs 517.9 Cr	-60.88% YoY

Source: company filing for Natco Pharma Q2 Results FY27, 13 November 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Natco Pharma Q2 Results: What Stands Out

Revenue down: Natco Pharma reported Rs 967.30 Cr against Rs 1,363.00 Cr a year earlier, a YoY change of 29.03%.
Net profit: net profit fell 60.88% YoY to Rs 202.60 Cr from Rs 517.90 Cr.
Operating Profit: the Operating Profit line came in at Rs 257.90 Cr against Rs 579.20 Cr a year earlier, a YoY change of 55.47%.
YoY growth: revenue moved 29.03% and net profit moved 60.88% YoY in Natco Pharma Q2 Results FY27, as the declared numbers show.
Next step: the performance analysis below explains how these figures sit together.

Natco Pharma Q2 Results FY27: Performance Analysis

Natco Pharma posted revenue of Rs 967.30 Cr in the July to September 2026 quarter, which fell 29.03% YoY to Rs 967.30 Cr from Rs 1,363.00 Cr, while net profit fell 60.88% YoY to Rs 202.60 Cr from Rs 517.90 Cr. These are the declared quarterly results for the company, and they form the base for everything that follows.

In Natco Pharma Q2 Results FY27, the revenue line and the profit lines tell the story together. Revenue shows no YoY growth, as it fell 29.03%, and net profit shows a 60.88% YoY change from Rs 517.90 Cr in the same quarter last year. Investors tracking the Consolidated results will weigh both lines. Both come from the same filing and are measured against the same quarter a year earlier, which keeps the comparison like for like.

The next disclosures will show whether the Natco Pharma Q2 Results pattern repeats, and Natco Pharma Q2 Results remains the reference for that comparison. The Operating Profit line adds a third reading at Rs 257.90 Cr against Rs 579.20 Cr. This results analysis now turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Return on Equity – Return on equity was 16.30% in FY26. The results analysis uses this disclosed factor as one reference point for the quarter.

Return on Capital Employed – Return on capital employed was 17.16% in FY26. In the quarterly results it is read alongside the revenue and net profit lines, without claiming a cause.

Operating Profit Line – Operating Profit moved 55.47% YoY to Rs 257.90 Cr from Rs 579.20 Cr. It is quoted as supplied and sits next to the other figures behind Natco Pharma Q2 Results FY27.

FY27 Outlook After Natco Pharma Q2 Results

The FY27 view rests on the figures declared so far and on how later quarters add to them. Full-year net profit will depend on subsequent quarters, and the Q2 quarter is one input into that picture. Each new quarter adds a data point to the FY27 record, so the declared figures are best read as one part of a developing year.

The results analysis for Natco Pharma will be easier to extend once the next quarter is declared. Univest Screener carries Natco Pharma updates, and net profit trends are the first item to compare against Rs 202.60 Cr. The risks that follow are the ones to keep in view.

Key Risks to Watch After Natco Pharma Q2 Results FY27

Revenue Decline

Revenue declined 29.0% year on year to Rs 967.30 Cr in the latest quarter. This is one of the points to track in the next disclosures after Natco Pharma Q2 Results FY27.

Net Profit Decline

Net profit fell 60.9% year on year to Rs 202.60 Cr. It sits beside the YoY growth figures reported for revenue and net profit.

Narrowing Net Profit Margin

Net profit margin narrowed to 20.9% from 38.0% in the comparison quarter. It is quoted as supplied and is read together with the other figures in this article.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Natco Pharma Q2 Results FY27 sit on a consolidated basis and show revenue of Rs 967.30 Cr with PAT of Rs 202.60 Cr. The quarterly results give investors a clear base to compare against the next quarter, and Natco Pharma Q2 Results remains the reference for that comparison. Investors should consult a SEBI-registered advisor before acting.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions on Natco Pharma Q2 Results FY27

What are Natco Pharma Q2 Results FY27?

Ans. Natco Pharma Q2 Results FY27 are the Consolidated quarterly results of Natco Pharma for July to September 2026, declared on 13 November 2026. Also, it is covered in the Financial Highlights table.

What is the results date for Natco Pharma Q2 Results FY27?

Ans. The results date for Natco Pharma Q2 Results FY27 is 13 November 2026, when Natco Pharma declared the quarter’s numbers. This means the figures reflect July to September 2026, as covered in the Quick Answer.

What revenue was reported in Natco Pharma Q2 Results FY27?

Ans. Natco Pharma reported revenue of Rs 967.30 Cr in Natco Pharma Q2 Results FY27, against Rs 1,363.00 Cr a year earlier. Alongside this, the 29.03% YoY change is covered in the Performance Analysis section.

What net profit was reported in Natco Pharma Q2 Results FY27?

Ans. In Natco Pharma Q2 Results FY27, Natco Pharma reported net profit of Rs 202.60 Cr. This compares with Rs 517.90 Cr in the same quarter last year, as the Key Takeaways section shows.

How much YoY growth did revenue show in Natco Pharma Q2 Results FY27?

Ans. Revenue in Natco Pharma Q2 Results FY27 showed no YoY growth, as it fell 29.03%, from Rs 1,363.00 Cr to Rs 967.30 Cr. Also, it is covered in the Performance Analysis section.

Did net profit rise or fall in Natco Pharma Q2 Results?

Ans. Natco Pharma Q2 Results show that net profit fell 60.88% YoY to Rs 202.60 Cr from Rs 517.90 Cr. This means the net profit line is read together with revenue, as the Performance Analysis section explains.

What was the Operating Profit in Natco Pharma Q2 Results FY27?

Ans. The Operating Profit in Natco Pharma Q2 Results FY27 was Rs 257.90 Cr, against Rs 579.20 Cr a year earlier, a YoY change of 55.47%. This line is discussed in the Performance Analysis section.

Are Natco Pharma Q2 Results consolidated results or standalone results?

Ans. Natco Pharma Q2 Results are consolidated results, so every revenue and net profit figure here follows that basis. Alongside this, the Quick Answer and the Conclusion both state the consolidated basis.

What business factors shaped Natco Pharma Q2 Results FY27?

Ans. The disclosed business factors for Natco Pharma Q2 Results FY27 are return on equity, return on capital employed and operating profit line, as listed for Natco Pharma. These are described under the Key Business Factors section.

What are the key risks after Natco Pharma Q2 Results FY27?

Ans. The risks to watch after Natco Pharma Q2 Results FY27 are revenue decline, net profit decline and narrowing net profit margin. Each one is described under the Key Risks to Watch section.

What is the outlook after Natco Pharma Q2 Results?

Ans. The FY27 outlook after Natco Pharma Q2 Results depends on how later quarters add to the Q2 figures. So full-year net profit will be shaped by subsequent quarters, as the Outlook section explains.

Where can I find the complete Natco Pharma Q2 Results FY27 data?

Ans. The complete Natco Pharma Q2 Results FY27 data, including revenue, PAT and YoY change, sits in the Financial Highlights table of this article. Alongside this, the Univest stock page for Natco Pharma carries the wider company details.

Author: Harsh Piplani

I am Harsh Piplani, an Assistant Content Manager with over 5 years of experience in crafting impactful, result-driven content. I hold a B.Com (Hons) degree and have worked across diverse industries, including education, fintech, healthcare, jewellery, and more. I specialise in content strategy, SEO, and optimisation, ensuring that every piece I create is not just well-written but also well-ranked. I believe content should do more than fill space so as to drive traffic, build authority, and support business growth. I enjoy turning complex ideas into clear, engaging narratives, and, as I like to say, I know how to spin words like a web to influence, structured, strategic, and impossible to ignore. For me, great content sits at the intersection of creativity and performance.